Michio Kaku: the brain “could be an open book”

Twelve years after he described a network that would carry feelings between people, Michio Kaku told Velco Dar how far the science still has to travel, and that he is certain it will arrive.

Policy & Regulation

FDA workshop uses ALS brain implants as its case study for small device trials

At a September FDA workshop on rare disease statistics, the FDA's background paper on device studies used brain-computer interfaces for ALS as its case example for testing devices in small populations. An FDA official said more uncertainty before approval may be acceptable when it is paired with post-market data collection, Synchron's Adam Fry said he does not think implant trials can be blinded effectively or ethically, and Paradromics said it is using its Connect-One study to design the measures for its pivotal trial.

Nov 17 · 9 min read

Market Moves

Science Corporation raises $400 million to bring its vision implant to the US

Science Corporation, the brain-computer interface company co-founded by former Neuralink president Max Hodak, announced a $400 million Series D on 17 November 2026 from investors including Khosla Ventures, the Ackman Oxman Institute and hospital operator Tenet Healthcare. The money will widen sales of its PRIMA retinal implant in Europe and prepare a US launch through the FDA's Humanitarian Device Exemption. TechCrunch and Bloomberg reported a $3.5 billion valuation.

Nov 17 · 5 min read

Research

Three US labs will present brain implants that restore communication at Neuroscience 2026

Brain implant researchers from UC Davis, Massachusetts General Hospital and Emory University will present at a Society for Neuroscience briefing on 17 November: a synthetic voice that captures pitch, a completely locked-in person who communicated independently for more than a year, and brain-to-text decoding that works even on an iPhone.

Nov 16 · 6 min read

Industry News

Precision Neuroscience partners with ALS charity Team Gleason

Precision Neuroscience and Team Gleason, the ALS charity founded by former New Orleans Saints player Steve Gleason, announced a partnership on 13 November 2026. People living with ALS, their families and caregivers will get a structured way to give feedback on Precision's brain-computer interface while it is in development, and the two will run joint education on its Layer 7 system for patients and clinicians, starting at the American Speech-Language-Hearing Association convention. Team Gleason first partnered with Synchron in 2022.

Nov 15 · 3 min read

Industry News

Neuralink adds chronic stroke to a new US implant trial

Neuralink has registered PRIME2, a US early feasibility study of its N1 implant that adds people with chronic ischaemic stroke to those with spinal cord injury and ALS. Up to 10 participants at up to five US sites will use the implant to control a computer cursor or virtual keyboard, starting at the University of Miami. The first version of the registry entry required a stroke at least 12 months before screening with lasting weakness in the arm that was dominant before it; a version posted two days later shortened the criteria. Stroke affects far more people than the conditions Neuralink's first US trial covered.

Nov 13 · 5 min read

Market Moves

Synchron's long road to reaching the brain through a blood vessel

Synchron began with a cold email from Tom Oxley to DARPA in 2011 and a US$1 million offer to build a brain implant that travels through the veins. Fifteen years on it has put its first-generation Stentrode into ten people in Melbourne and the United States, raised US$345 million, connected its implant to Apple devices, Amazon's Alexa and OpenAI's models, and started trials of a fully wireless second-generation device. Enrolment in its US and Australian trials is paused while Synchron upgrades the hardware, and the company says it will restart once that work is finished.

Nov 13 · 14 min read

Industry News

Synchron pauses enrolment in its Stentrode trials over a problem with the implant's lead

Synchron has paused enrolment in trials of its updated, fully wireless Stentrode after a performance problem with the lead, the cable that carries signals from the Stentrode to the implanted electronics. The company says it chose to pause on its own and that no device-related safety issues have been found, and it is upgrading the whole system before restarting. WIRED reported that Synchron is also cutting jobs and scaling back in New York while building a San Diego team for a new device. Separately, the registry entry for its Canadian study lists it as terminated in September for insufficient recruitment.

Nov 13 · 4 min read

Market Moves

Chinese startup Junrou raises nearly RMB 100 million for brain electrodes steered by magnets

Junrou Technology, founded in 2025 by Liu Zhiyuan of the Shenzhen Institutes of Advanced Technology, has closed an angel-plus round of nearly RMB 100 million led by Shunwei Capital, with GL Ventures, humanoid robot maker AgiBot and Nansha Qisheng following. The company is commercialising NeuroWorm, a soft fibre electrode published in Nature in September 2025 that can be steered through tissue by an external magnet. It plans an investigator-initiated clinical study in 2027, starting with epilepsy and depression, and has also developed electronic skin for robot hands.

Nov 12 · 4 min read